Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NMT submits PMA (premarket approval application) for next-generation PFO (patent foramen ovale) implant:

This article was originally published in Clinica

Executive Summary

NMT Medical has filed a premarket approval (PMA) application with the US FDA for its STARFlex implant, a next-generation version of its minimally invasive device for the closing of a hole in the heart, called patent foramen ovale (PFO). A multicentre study supporting the FDA submission showed that 98% of the patients treated with the implant had complete PFO closure at follow up, says John Ahern NMT's president and CEO. The Boston, Massachusetts firm gained FDA approval of its earlier generation PFO closure device, CardioSEAL, under Humanitarian Device Exemption regulations last year (see Clinica No 894, p 14).

You may also be interested in...

What Lies Ahead: COVID-19 Vaccination Challenges

The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.

P&G: Sales Growth Strongest When Rising Tide Floats All Competitors Across All Categories

P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts